Dr. Petros Grivas is a medical oncologist at Seattle Cancer Care Alliance, Clinical Director of the Genitourinary Cancers Program, and Associate Professor at the University of Washington School of Medicine. He is also an Associate Member of the Clinical Research Division at Fred Hutchinson Cancer Research Center.
His expertise is in treating genitourinary cancers such as bladder cancer, prostate cancer and testicular cancer. His clinical research helped lead to FDA approval of new drugs to treat the most common type of bladder cancer. Dr. Grivas currently leads clinical trials that investigate the use of checkpoint inhibitors. These immunotherapy drugs release the brakes on a patient’s immune system and help it mount a better response to cancer.
Disclosures
- Institutional research funding: Bavarian Nordic; BMS; Clovis Oncology; Debiopharm; Immunomedics; Pfizer; Merck; QED Therapeutics; GlaxoSmithKline; Mirati Therapeutics; Kure It Cancer Research
- Consulting: AstraZeneca; Dyania Health; EMD Serono; Immunomedics; Infinity Pharmaceuticals; Janssen; Merck; Mirati Therapeutics; Genentech; Pfizer; Seattle Genetics